Immatics N.V.
General ticker "IMTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $903.6M (TTM average)
Immatics N.V. does not follow the US Stock Market performance with the rate: -9.6%.
Estimated limits based on current volatility of 4.0%: low 4.17$, high 4.52$
Factors to consider:
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.13$, 9.10$]
- 2025-12-31 to 2026-12-31 estimated range: [3.73$, 8.19$]
Financial Metrics affecting the IMTX estimates:
- Positive: 0.04 < Non-GAAP EPS, $ of 0.14
- Negative: Operating cash flow per share per price, % of -17.18 <= 1.79
- Positive: -3.20 < Investing cash flow per share, $ of -1.50
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry operating cash flow per share per price (median), % of -21.10 <= 2.82
- Negative: negative Operating income
- Negative: Industry earnings per price (median), % of -27.42 <= 0
- Positive: -1.21 < Return on assets ratio (scaled to [-100,100]) of 2.14
- Negative: Inventory ratio change, % of 46.30 > 1.05
Short-term IMTX quotes
Long-term IMTX plot with estimates
Financial data
YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
---|---|---|---|
Operating Revenue | €172.83MM | €54.00MM | €155.84MM |
Operating Expenses | €142.88MM | €155.72MM | €194.45MM |
Operating Income | €29.95MM | €-101.72MM | €-38.62MM |
Non-Operating Income | €12.08MM | €4.73MM | €59.96MM |
Interest Expense | €8.28MM | €0.83MM | €0.89MM |
R&D Expense | €106.78MM | €118.66MM | €148.08MM |
Income(Loss) | €42.04MM | €-96.99MM | €21.35MM |
Taxes | €4.55MM | €-2.35MM | €6.13MM |
Profit(Loss)* | €37.51MM | €-96.99MM | €15.22MM |
Stockholders Equity | €213.16MM | €225.08MM | €574.84MM |
Inventory | €0.00MM | €0.00MM | €0.00MM |
Assets | €407.82MM | €509.96MM | €696.15MM |
Operating Cash Flow | €100.13MM | €18.23MM | €-158.03MM |
Capital expenditure | €6.21MM | €30.96MM | €16.48MM |
Investing Cash Flow | €-209.79MM | €-31.39MM | €-152.39MM |
Financing Cash Flow | €123.71MM | €84.52MM | €319.68MM |
Earnings Per Share** | €0.56 | €-1.20 | €0.14 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.